Confirmed objective response rate (cORR) of 75% overall and   93% for the proposed Phase 3 regimen (zanidatamab + CAPOX/FP) Median duration of response (mDOR) of 16.4 months and median progression free survival (mPFS) of 12 months Data support zanidatamab + chemotherapy as the foundation of a  Continue Reading

Abstract data demonstrate encouraging antitumor activity in first-line GEA Full ESMO presentation available September 16 at 8:30 am CEST , 2:30 am ET Conference call and webcast with principal investigator, Dr. Geoffrey Ku , on September 16 at 7:30 am ET VANCOUVER, British Columbia --(BUSINESS  Continue Reading

VANCOUVER, British Columbia --(BUSINESS WIRE)--Aug. 4, 2021-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the second quarter ended June 30, 2021 .  Continue Reading

VANCOUVER, British Columbia --(BUSINESS WIRE)--Aug. 3, 2021-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Janssen Biotech, Inc. (Janssen) dosed the first patient with JNJ-78278343, a bispecific antibody  Continue Reading

VANCOUVER, British Columbia --(BUSINESS WIRE)--Jul. 28, 2021-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the first patient has been dosed with zanidatamab in combination with Tukysa ® (tucatinib) and  Continue Reading

VANCOUVER, British Columbia --(BUSINESS WIRE)--Jul. 8, 2021-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will present at the upcoming Ladenburg Thalmann Healthcare Conference on July 14, 2021  Continue Reading

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will present at the upcoming Jefferies Virtual Healthcare Conference taking place June 1-4, 2021.  Continue Reading

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical‑stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General Meeting of Shareholders  Continue Reading

Download the PDF version PDF Format (opens in new window) ANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2021.  Continue Reading

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Diana Hausman, M.D., will be transitioning out of her role as Zymeworks’ Chief Medical Officer (CMO) and assuming  Continue Reading